FUNDAMENTAL RESEARCH

Fundamental research carried out at B&A Therapeutics is conducted in collaboration with researchers from Inmed (Mediterranean Institute of Neurobiology, Marseille, France). It concerns early electrophysiological signs in the basal ganglia of Parkinson’s disease rodent models.

In the medium term, B&A Therapeutics will develop its activities in fundamental research recruiting technicians/engineers and researchers, which will strengthen the Company’s intellectual property.

PUBLICATIONS

Dehorter N, Lozovaya N, Mdzomba BJ, Michel FJ, Lopez C, Tsintsadze V, Tsintsadze T, Klinkenberg M, Gispert S, Auburger G, Hammond C.

Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum.

J Neurosci. 2012 Dec 12;32(50):18047-53.

Read the article

Plus d'informations

PUBLICATIONS

Dehorter N, Guigoni C, Lopez C, Hirsch J, EusebioA, Ben-Ari Y, Hammond C.

Dopamine-deprived striatal GABAergicinterneurons burst and generate repetitive gigantic IPSCs in medium spiny neurons.

J Neurosci. 2009 Jun 17;29(24):7776-87.

Read the article
(article en anglais)

Plus d'informations

CLINICAL RESEARCH

Clinical research conducted by B&A Therapeutics focuses on the development of innovative therapeutic approaches to ameliorate the symptoms of Parkinson’s disease. Current treatments of the pathology are in a very large majority centered on the dopaminergic system (dopamine precursors or L-DOPA, dopamine agonists, blockers of dopamine re-uptake…). Although effective, they do not correct all symptoms of the pathology and can lead to side effects. B&A Therapeutics proposes to develop a non-dopaminergic treatment that, as a supplement to standard treatments, could improve motor symptoms such as gait and freezing (unexpected immobility with trampling) of patients.

Following encouraging results obtained from a pilot study conducted in 4 patients with Parkinson’s disease in collaboration with the University Hospital Center (UHC) of Nantes (Damier P et al., 2016), B&A Therapeutics is currently in an active phase of fund-raising to finance a phase II clinical trial that could confirm the therapeutic efficacy of Bumetanide. This randomized double-blind placebo-controlled study should be conducted in 60 patients in a dozen specialized centers throughout France.

In the long term, B&A Therapeutics aims at placing the drug it develops on the market as a supplement to standard treatments. This would lead to improve significantly the quality of life of patients with Parkinson’s disease with few side effects.

PUBLICATIONS

Damier P, Hammond C, Ben-Ari Y.

Bumetanide to Treat Parkinson Disease : A Report of 4 Cases.

Clin Neuropharmacol. 2016 Jan-Feb;39(1):57-9.

Read the article
(article en anglais)

Plus d'informations